References
- Locatelli F, Schrappe M, Bernardo ME, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14):2807–2816.
- Bertaina A, Vinti L, Strocchio L, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176(4):629–636.
- Wiemels J. Perspectives on the causes of childhood leukemia. Chem Biol Interact. 2012;196(3):59–67.
- Eswaran J, Sinclair P, Heidenreich O, et al. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia. 2015;29(8):1623–1631.
- Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 2012;26(3):123–135.
- Le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008;14(1):47–58.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Lilljebjorn H, Fioretos T. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia. Blood. 2017;130(12):1395–1401.
- Ghazavi F, Lammens T, Van Roy N, et al. Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. Exp Hematol. 2015;43(8):640–653.
- Miller DM, Thomas SD, Islam A, et al. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18(20):5546–5553.
- Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives. Pediatr Hematol Oncol. 2013;30(6):465–483.
- Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56–67.
- Iezzi S, Fanciulli M. Discovering Che-1/AATF: a new attractive target for cancer therapy. Front Genet. 2015;6:141.
- Bruno T, De Nicola F, Iezzi S, et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell. 2006;10(6):473–486.
- Bruno T, Desantis A, Bossi G, et al. Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer Cell. 2010;18(2):122–134.
- De Nicola F, Bruno T, Iezzi S, et al. The prolyl isomerase Pin1 affects Che-1 stability in response to apoptotic DNA damage. J Biol Chem. 2007;282(27):19685–19691.
- Di Certo MG, Corbi N, Bruno T, et al. NRAGE associates with the anti-apoptotic factor Che-1 and regulates its degradation to induce cell death. J Cell Sci. 2007;120(Pt11):1852–1858.
- Desantis A, Bruno T, Catena V, et al. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J. 2015;34(9):1214–1230.
- Sorino C, Bruno T, Desantis A, et al. Centrosomal Che-1 protein is involved in the regulation of mitosis and DNA damage response by mediating pericentrin (PCNT)-dependent Chk1 protein localization. J Biol Chem. 2013;288(32):23348–23357.
- Bruno T, Valerio M, Casadei L, et al. Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization.J. Exp Clin Can Res. 2017;36(1):32.
- Folgiero V, Sorino C, Pallocca M, et al. Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia. EMBO Rep. 2018;19(3).
- Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68–79.
- Sabò A, Kress TR, Pelizzola M, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014;511(7510):488–492.
- Rehe K, Wilson K, Bomken S, et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med. 2013;5(1):38–51.